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Objective: To estimate the lifetime risk of undergoing primary total hip (THR) or knee (TKR) replacement
in the UK.
Method: A Population-based cohort study of 25,845 patients who had undergone a THR and 23,260
patients who had undergone a TKR between 1991 and 2006, using data from the UK General Practice
Research Database.
Results: The estimated mortality-adjusted lifetime risk of THR at age 50 for the year 2005 was 11.6%
(95% CI: 11.1, 12.1) for women and 7.1% (95% CI: 6.7, 7.5) for men. For TKR the risks were 10.8% (95% CI:
10.3, 11.3) for women and 8.1% (95% CI: 7.6, 8.5) for men. Between 1991 and 2006, the lifetime risk of THR
at age 50 rose from 4.0% (95% CI: 3.5, 4.4) to 11.1% (95% CI: 10.6, 11.6) for women and for men from 2.2%
(95% CI: 1.8, 2.5) to 6.6% (95% CI: 6.2, 7.0). Over the same period, for TKR the risk for women increased
from 2.9% (95% CI: 2.6, 3.3) to 10.6% (95% CI: 10.1, 11.1) and for men from 1.8% (95% CI: 1.5, 2.2) to 7.7%
(95% CI: 7.3, 8.2).
Conclusion: The lifetime risk of undergoing THR or TKR is estimated to be substantially less than the risk
of developing symptomatic hip or knee osteoarthritis. For the knee, the difference between these risk
estimates is particularly wide. The reasons for the size of these differences are not clear, and further work
is needed to quantify the extent of latent demand for these cost-effective and established interventions
among the population with symptomatic osteoarthritis of the hip or knee.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.What is already known on this topic
Total hip (THR) and knee (TKR) replacements are among the
most successful and reliable orthopaedic procedures for joint pain
relief in patients with advanced osteoarthritis.
The lifetime risk of developing knee and hip osteoarthritis has
already been estimated at 45% and 25% respectively.
Register data and published incidence rates from the UK show
an increasing trend in hip and knee replacement but there is no
corresponding data on lifetime risk.
What this study adds
The lifetime risk of undergoing a THR or TKR in the UK is esti-
mated at between 5 and 10 percent, which is substantially less thanN.K. Arden, NIHR Musculo-
, Nufﬁeld Orthopaedic Centre,
7851; Fax: 44-1865-227966.
. Arden).
s Research Society International. Pthe risk of hip or knee osteoarthritis. Between 1991 and 2006 there
is an upward trend in risk.
The lifetime risk of hip or knee osteoarthritis is greater than that
for total hip or knee replacement.Introduction
The lifetime risk of developing knee osteoarthritis has been
estimated at 45%1, with the corresponding ﬁgure for osteoarthritis
of the hip at 25%2. The magnitude of these risks is not surprising
given that hip and knee osteoarthritis has such a high prevalence
among elderly people3,4 and the average life expectancy in the UK
population is over 75 years. Joint replacement surgery for both hip
and knee is an efﬁcacious and cost-effective treatment for end stage
joint disease5 and the number of primary total joint replacements
being performed per annum in the UK is currently rising and has
been predicted to continue to increase by as much as 50% by 20266.
Historically total hip and knee replacements have been amongst
the most successful and reliable orthopaedic interventions for painublished by Elsevier Ltd. All rights reserved.
Table I
Clinical and Demographic characteristics e for subjects aged 50 and over
Total Hip Replacement Total Knee Replacement
Female Male Female Male
N¼ 16303 N¼ 9544 N¼ 13811 N¼ 9449
Age (mean, SD) 71.6 (9.4) 69.1 (9.1) 71.6 (8.6) 70.2 (8.3)
Gender (%) 63.1 36.9 59.4 40.6
BMI* (mean, SD) 27.0 (5.3) 27.5 (4.3) 29.2 (5.6) 28.5 (4.4)
No. of comorbid conditions (%):
0 37.1% 39.9% 34.2% 36.6%
1 38.7% 37.2% 38.6% 37.0%
2þ 24.2% 22.9% 27.2% 26.5%
Indications for surgeryy (%):
Rheumatoid
arthritis
3.0% 1.3% 4.3% 2.0%
Osteoarthritis 93.4% 96.7% 89.5% 94.2%
Others 3.6% 2.0% 6.1% 3.7%
* BMI only used if within 1 year pre-surgery - available for 85% of subjects
y For those subjects where an indication could be reliably ascertained
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prosthesis survival at 10 years7.
Given that osteoarthritis is now the most frequent indication for
total hip or knee arthroplasty in the UK8 (over 90% for hips and over
95% for knees), it might be expected that the lifetime risk of
undergoing this form of surgery is substantial, yet we are unaware
of any existing population-based estimates for this risk. Although
demand for such surgery has usually outstripped supply, the
number of operations performed is still considerable, with over
160,000 hip and knee replacements carried out in England and
Wales in the 12 months to April 20109.
Lifetime risk is a concept which is easily interpretable by
patients, clinicians and policymakers, arguably providing a more
patient-centred measure of risk for the onset of disease or the
occurrence of a speciﬁc event10. For most lay persons, it is easier to
understand a lifetime risk percentage than an age-speciﬁc inci-
dence rate. A lifetime risk estimate can be made more informative
by additionally calculating interval risks (e.g., 10 years) at different
ages to establish the periods of greatest risk during the lifetime.
The primary aim of this study was to use data from the General
Practice Research Database (GPRD), combined with national Ofﬁce
for National Statistics (ONS) mortality data to provide simple esti-
mates for the lifetime risk of undergoing a primary THR or TKR
replacement in the UK. A secondary aim was to describe temporal
changes in these estimated risks between 1991 and 2006.
Method
Participants
We used data obtained from the GPRD. The GPRD comprises the
entire computerized medical records of a sample of patients
attending general practitioners (GPs) in the UK covering a pop-
ulation of 6.5 million patients from 433 contributing practices
chosen to be representative of thewider UK population11. GPs in the
UK play a key role in the delivery of healthcare by providing primary
care and referral to specialist hospital services. Patients are regis-
tered with one practice that stores medical information from
primary care andhospital attendances. TheGPRD is administeredby
theMedicines andHealthcare products Regulatory Agency (MHRA).
The GPRD records contain all clinical and referral events in both
primary and secondary care in addition to comprehensive demo-
graphic information, prescription data, and hospital admissions.
Data is stored using Read and OXMIS codes for diseases that are
cross-referenced to the International Classiﬁcation of Diseases
(ICD-9). Read codes are used as the standard clinical terminology
system within UK primary care. Only practices that pass quality
control are used as part of the GPRD database. Deleting or encoding
personal and clinic identiﬁers ensures the conﬁdentiality of infor-
mation in the GPRD. Complex survey methods were not required
for this analysis because the GPRD comprises entire general prac-
tice populations rather than probability-based samples of patients.
We identiﬁed all patients in the database with a diagnosis code
for total hip or knee arthroplasty from 1991 until the end of 2006.
Read/OXMIS codes were used to identify primary THRs and TKRs.
Patients were included in the analysis if aged 50 years or over at the
time of the replacement. Participant demographics including age,
gender, body mass index (BMI) and smoking status were collated.
We also obtained gender-speciﬁc all-cause mortality data from the
ONS12 for the time period 1991e2006.
Analysis
TheGPRDdatawas aggregated into single-year age intervals. The
age label was deﬁned as age at last birthday at the end of a calendaryear, starting at age 50. Consistent deﬁnitions were applied to the
deathdata and exposed to risk. Incidence rates for joint replacement
were computed by dividing the count of primary THRs and TKRs in
the GPRD data by the corresponding amount of person time spent
by those in the entire GPRD populationwho matched the age band,
gender and time interval of interest. We computed the lifetime risk
of replacement at 50 years of age separately for hip and knee. This
was achieved by a life table method similar to that used by van Staa
and colleagues13, applying the incidence rates for replacement and
the rates for all-cause mortality as multiple decrements at 1-year
age intervals. The resulting counts of THR and TKR for the hypo-
thetical life table populationwere then summed and divided by the
life table population base to produce estimates of lifetime risk from
age 50. Conﬁdence intervals at the 95% level were estimated under
a Poissonmodel14, which is the standard assumption for count data.
Risks were estimated separately for gender and hip/knee. This
procedure was repeated with 60, 70 and 80 years of age as the
starting point for the risk of replacement. Additionally, we
computed 10-year risk percentages from age 50 up to age 80. Esti-
mates were tabulated using 2005 replacement and mortality data
due to the possibility of boundary effects with the GPRD data for
2006, although we additionally calculated risk percentages based
on the replacement counts and person-time for the entire study
period 1991e2006. All estimates for single calendar years used
mortality data matched to the same calendar year, but for the
estimates based on the entire study period we used 2006 mortality
rates, which were themost recent rates available falling within that
period, but a sensitivity analysis using 1991mortality rates was also
carried out. Finally, lifetime risks of THR and TKR stratiﬁed by
gender for individual calendar years, were estimated in order to
compare temporal trends.
All statistical analyses were performed in Microsoft Excel 2003
(Microsoft Corporation, Redmond, WA), SAS version 9.1.3 (SAS
Institute Inc., Cary, NC) and R (R Foundation for Statistical
Computing, Vienna, Austria).Results
Participant demographics
We identiﬁed 49,105 patients from the database who had
undergone a THR (N¼ 25,845) or TKR (N¼ 23,260) during the
study period. The average age at replacement was similar in both
THR and TKR cohorts but the proportion of women was greater for
both THR and TKR (Table I). For thosewith a recorded pre-operative
Fig. 1. Temporal trends in the estimated lifetime risk at age 50 of undergoing primary
total hip or knee replacement surgery based on age and gender-speciﬁc incidence rates
from GPRD data, adjusted for mortality.
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and 37% for TKR.
Lifetime risks
Using rates from 2005, we estimated that the mortality-
adjusted lifetime risk of THR at age 50 was 11.6% for women and
7.1% for men (see Table II). For TKR the risk was estimated at 10.8%
for women and 8.1% for men. The lifetime risk decreases with
increasing age for both THR and TKR in men and women. At age 80
the gender gap in risk of THR has reduced to 40% higher for women
than men (22% higher for TKR). Estimated risk percentages at ages
50, 60, 70 and 80 are presented in Table II.
For the aggregated data over the period 1991 and 2006, the
mortality-adjusted lifetime risk of THR at age 50 was estimated at
8.3% for women and 5.2% for men. For TKR the risk was estimated at
7.0% for women and 5.2% for men. The gender gap in the estimates
obtained for the whole study period was similar to those for the
2005 estimates. Mortality data from 2006 was used for the whole
study period estimates. As a sensitivity analysis, these estimates
were recalculated using 1991 mortality data, but this only resulted
in a small reduction in the lifetime risk estimates of between 0.6
and 0.8 percentage points at age 50 and a reduction of 0.2e0.3 at
age 80. These reductions were seen for both THR and TKR and for
men and women.
Between 1991 and 2006, the lifetime risk of THR at age 50 rose
from 4.0% (95% CI: 3.0, 5.0) to 11.1% (95% CI: 9.9, 12.2) for women
and for men from 2.2% (95% CI: 1.4, 3.0) to 6.6% (95% CI: 5.7, 7.5).
Over the same period, for TKR the risk for women increased from
2.9% (95% CI: 2.1, 3.8) to 10.6% (95% CI: 9.5, 11.7) and for men from
1.8% (95% CI: 1.1, 2.6) to 7.7% (95% CI: 6.8, 8.7). Lifetime risks at age
50 for each year of the study period are presented in Fig. 1.
When shortening the time horizon to 10 years rather than the
remainder of life, it can be seen (Table III) that in 2005 the risk of
a 50-year old female undergoing a THR by age 60 is low (1.1%, 95%
CI: 0.8, 1.4) compared with the 10-year risk for an 80-year old (3.5%,
95% CI: 2.7, 4.3). Ten-year TKR risks are slightly higher than THR
risks for men aged 60 and over, but for women they are more
similar. Figure. 2 shows the temporal trend in 10-year risk of THR
for women. Single-year estimates of 10-year risk at ages 50, 60, 70
and 80 are presented between 1991 and 2006 at ﬁve-yearly inter-
vals. Figure 2 also shows that among these four starting ages, the
10-year risk of undergoing THR is consistently highest for 70-year
old women and lowest for 50-year old women between 1991 and
2006. This was also true for 10-year THR risks for men and for 10-
year TKR risks for both women and men.
Discussion
Summary of results
This study presents population-based estimates for the lifetime
risk of undergoing total hip and knee arthroplasty in the UnitedTable II
Estimated lifetime risk (percentage with 95% conﬁdence intervals) of undergoing
primary total hip or knee replacement surgery based on age and gender-speciﬁc




Risk of primary total
hip replacement (%)
Risk of primary total
knee replacement (%)
Female Male Female Male
50 11.6 (10.4,12.7) 7.1 (6.2,8.0) 10.8 (9.7,11.9) 8.1 (7.1,9.1)
60 10.8 (9.7,12.0) 6.7 (5.8,7.7) 10.1 (9.0,11.2) 7.9 (6.9,8.9)
70 8.1 (7.1,9.2) 5.3 (4.3,6.2) 7.8 (6.7,8.8) 6.2 (5.2,7.2)
80 3.8 (3.0,4.7) 2.7 (1.8,3.6) 3.3 (2.6,4.1) 2.7 (1.8,3.6)Kingdom for those aged 50 and over. The lifetime risk estimates for
arthroplasties are substantially less than the corresponding lifetime
risks for clinical osteoarthritis. Temporal trends in lifetime risk of
THR and TKR between 1991 and 2006 show a steady rise, with rates
for women being consistently higher than for men.
The estimation of lifetime risks for major diseases and events is
well established, including coronary heart disease (CHD)15, cancer16,
and fracture13,17. Althoughpublished incidence rates exist for hip and
knee replacement in the UK8,18 and internationally6,19e21, we are
unaware of any lifetime risk estimates available in the literature for
undergoing these surgical procedures. The estimates presented here
suggest a lifetime risk of THR or TKR for women or men aged 50
living in the UK of 10e11% and 6e7% respectively, based on GPRD
data from 2005. These estimates are considerably less than the
lifetime risks for osteoarthritis of the hip (HOA) and knee (KOA)
which in the United States have been estimated at 25%2 and 45%1
respectively, based on a symptomatic and radiographic (Kellgren/
Lawrence 2) diagnosis of osteoarthritis. Osteoarthritis is by far the
most common primary indication for THR and TKR, accounting for
93% and97% respectively of all such operations in England andWales
in 20099, with similar ﬁgures of 90% for THR and TKR reported in the
United States22.
The mismatch between the lifetime risks of such an established
intervention (THR/TKR) and its main indication (HOA/KOA) is
interesting, especially so for the knee given the much larger
difference in risks. There are a number of potential explanations for
the differences between these estimates, and we address each of
these in turn. Amajor part of the difference between risks estimates
for osteoarthritis and joint replacement may be related to the lack
of consensus on the severity of symptoms required for an indicationTable III
Estimated 10-year risk (percentage with 95% conﬁdence intervals) of undergoing
primary total hip or knee replacement surgery based on age and gender-speciﬁc




Risk of primary total
hip replacement (%)
Risk of primary total
knee replacement (%)
Female Male Female Male
50 1.1 (0.8,1.4) 0.8 (0.5,1.0) 1.1 (0.8,1.4) 0.6 (0.4,0.9)
60 3.5 (2.8,4.1) 2.2 (1.7,2.7) 3.1 (2.5,3.7) 2.6 (2.0,3.1)
70 5.2 (4.4,6.1) 3.5 (2.8,4.3) 5.2 (4.4,6.1) 4.4 (3.6,5.3)
80 3.5 (2.7,4.3) 2.4 (1.5,3.2) 3.2 (2.5,4.0) 2.6 (1.7,3.4)
Fig. 2. Temporal trends in the estimated 10-year risk for women of undergoing
primary total hip replacement surgery at current age 50, 60, 70 and 80 based on age
and gender-speciﬁc incidence rates from GPRD data, adjusted for mortality.
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osteoarthritis. Indications for surgery include end-stage joint
arthritis (typically a K/L grade of 3 or 4), a degree of mobility
affected by symptoms and persistent severe pain which has failed
to be relieved by non-surgical treatment24,25. An earlier
population-based study of TKR by Juni et al.26 in the south west of
England used an assessment of need based on the New Zealand
Score27, suggesting that differences in the perception of disease
severity may account for some of the underprovision reported by
the study team.
At least some of the disparity between the estimated risks of
knee osteoarthritis and TKR might be because not all of those with
radiographic and symptomatic OA require TKR surgery. There is a
considerable disparity between the presence and severity of
radiographic OA and symptoms: data from the Framingham Oste-
oarthritis demonstrated that only 59% of those with deﬁnite
radiographic knee OA (K/L grade 2) reported knee pain on most
days in the previous month3. Furthermore, there is now increasing
data to suggest that OA does not necessarily progress over time
such that many patients may never require surgery: data from the
Chingford study have demonstrated that 61% of patients with
radiographic OA do not progress radiographically over a period of
15 years28; that self-reported knee pain may resolve over a similar
time period in 30% of patients29 and that in a cross sectional survey
of patients diagnosed with clinical knee OA 29% did not report
clinically important symptoms30.
A further possibility is that some of this differential may be
related to unmet need for THR and TKR. Judge et al have estimated
the mismatch between need and provision of hip and knee
replacement surgery in the UK31,32 and attempts have beenmade to
explain such differences in terms of geographical and socio-
demographic characteristics33. A study based on UK data from the
late 1990s34,35 found that although there was little mismatch for
THR, there was a large mismatch between estimated need and
provision for TKR. The aforementioned paper by Juni et al26 adds
further support to this evidence. Although our GPRD data does not
extend further than 2006, data from the National Joint Registry9
show that for England and Wales, the years 2007e2010 have
seen a much slower growth in provision than was seen in the
period from 1995 to 20058. This suggests that the perceived gap
between need and provision is unlikely to have been substantially
narrowed in the time since the end 2006, the year on which our
most recent estimates of lifetime risk are based. This would dependon there having been no change in the risk of developing osteoar-
thritis over the same period.
Notwithstanding the explanations already offered for the
disparity between lifetime risk estimates for OA and THR/TKR,
there is also the issue of patient choice in whether to accept
a surgical intenvention, if it is offered. Research by Hawker and
colleagues in Canada36 examined OA patients’ perceptions of total
joint arthroplasty as an intervention, ﬁnding that willingness to
undergo surgery was associated with misperceptions about its
appropriateness. Another study by the same team found low rates
of willingness to undergo surgery among those with disabling
arthritis37. Studies in the UK have also shown that a substantial
proportion of those for whom THR/TKR is a suitable intervention
may not be willing to have surgery, with women less willing than
men38 and willingness to undergoTKR less than that for THR34. One
study26 reported that 32% of those considered for TKR were
unwilling, for a variety of reasons, to consider surgery as an option.
Finally, our lifetime risk estimates for THR and TKR are based on
data from the United Kingdom, yet we are making comparisons to
lifetime risks for osteoarthritis based on cohort data from the
United States. It is accepted that we are comparing data from
different countries and with different study designs, but the oste-
oarthritis risks estimated by Murphy et al1,2 are the only reliable,
large-scale estimates available for a developed population.
Strengths and potential limitations of the study
One of the strengths of this study is the data on which it was
based. The usefulness of registers and databases is highly dependent
on the quality of the data collection. The data imported into
the UK GPRD is in an extremely detailed, descriptive and well-
structured format which permits accurate interpretation. It is
accepted11,39 that the data subjects included in theGPRDare broadly
representative of the UK population as a whole with respect to
age, sex, socio-economic class and UK region. Further examples of
GPRD validation are given by van Staa and colleagues13,40,41.
The life table method of estimating lifetime risk is a standard
and straightforwardmethodwhich permitsmultiple decrements to
cater for competing risks. It can provide accurate estimates of risk,
particularly where the time interval between successive decre-
ments is small. However, it does not have the ﬂexibility in dealing
with predictor variables afforded by more sophisticated model-
based methods.
We chose to stratify only by age and gender, and the only
competing risk we considered was all cause mortality. Although
mortality for those with OA has been reported to be elevated
compared with the general population42, we used mortality for the
general population as our lifetime risks are estimated for such
a population and not speciﬁcally for the OA population. The quoted
lifetime risks of 25% and 45% for hip and knee osteoarthritis are
based on age 18 whereas our estimates of risk for THR and TKR are
from age 50. However, very few primary THR/TKR operations are
performed on those under the age of 50, and the majority of these
are indicated by trauma rather than osteoarthritis. To examine the
sensitivity of our estimates to survival bias, we computed lifetime
risks at ages 20, 30 and 40, ﬁnding virtually no difference between
risks estimates at those ages (approximately 0.05 of one percentage
point) and risks at age 50. There is no speciﬁc code for THR/TKR
performed in private practice as opposed to the NHS setting and we
cannot be certain that some operations may not have been recor-
ded. Our rates however are consistent with those from the NJR
which did record private operations.
Obesity was not used as a stratifying factor in our analysis. BMI
data is only available for the cohort who underwent THR or TKR
(respectively 25% and 37% obese), and is not available for the
D.J. Culliford et al. / Osteoarthritis and Cartilage 20 (2012) 519e524 523GPRD population which comprise the denominator in the THR/
TKR incidence rates from which our lifetime risk estimates are
derived. Furthermore, BMI data is not collected systematically for
GPRD data, and as a consequence is not available for approxi-
mately 15% of subjects. Hence direct statistical comparisons with
the baseline obesity proportion for the Johnston County cohort
(25%) in the osteoarthritis risk papers by Murphy et al1,2 are not
possible.
Care should be exercised in generalising these lifetime risk
results to countries and sub-populations where the patterns of
access to medical care are different from those in the UK. Within
the United States, for example, differing levels of health insurance
coverage may result in variability in the lifetime risk of THR/TKR.
The data we have used does not extend beyond the end of 2006,
and therefore one should be wary of generalising the results to
current patterns of THR/TKR utilisation. In particular, TKR rates are
now considerably higher than those for THR, but here we have
chosen to concentrate on the difference between the risks of
disease and intervention rather than any estimated differences
between THR and TKR.Conclusion
The lifetime risk of undergoing total hip or knee arthroplasty is
estimated to be substantially less than the risk of developing hip or
knee osteoarthritis, which is by far the most common indication for
such surgical interventions. The reasons for such a gap, which is
particularly wide in the case of total knee replacement, are not yet
clear, and further work is needed to establish the extent of any
latent demand for these cost-effective and established interven-
tions among the population with symptomatic osteoarthritis of the
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